Prognostic impact of baseline tumor size (BTS) on survival outcomes in patients (pts) with untreated advanced nonsmall cell lung cancer (NSCLC), PD-L1 ≥50%, treated with pembrolizumab alone

被引：0
|
作者：
Bureau, M. [1 ]
Chatelier, T. [2 ]
Perennec, T. [1 ]
Goronflot, T. [3 ]
Greilsamer, C. [4 ]
Chene, A-L. [5 ]
Affi, R. [1 ]
Bennouna, J. [1 ]
Pons-Tostivint, E. [1 ]
机构：
[1] Univ Hosp Nantes, Dept Pneumol, Thorac Med Oncol Funct Unit, Nantes, France
[2] Clin Mutualiste Estuaire, Med Oncol, St Nazaire, France
[3] Univ Hosp Nantes, Biostat Dept, Nantes, France
[4] Hosp La Roche Sur Yon, Med Oncol, La Roche Sur Yon, France
[5] Univ Hosp Nantes, Pneumol Dept, Nantes, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1295P
引用
收藏
页码：S1004 / S1004
页数：1
相关论文
共 50 条
  • [31] Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy
    Takamori, Shinkichi
    Takada, Kazuki
    Shimokawa, Mototsugu
    Matsubara, Taichi
    Haratake, Naoki
    Miura, Naoko
    Toyozawa, Ryo
    Yamaguchi, Masafumi
    Takenoyama, Mitsuhiro
    Yoneshima, Yasuto
    Tanaka, Kentaro
    Okamoto, Isamu
    Tagawa, Tetsuzo
    Mori, Masaki
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (08) : 2327 - 2334
  • [32] Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)
    Ferrara, R.
    Caramella, C.
    Texier, M.
    Audigier-Valette, C.
    Tessonnier, L.
    Mezquita, L.
    Lahmar, J.
    Mazieres, J.
    Zalcman, G.
    Brosseau, S.
    Westeel, V.
    Le Moulec, S.
    Leroy, L.
    Duchemann, B.
    Lefebvre, C.
    Veillon, R.
    Champiat, S.
    Ferte, C.
    Planchard, D.
    Boucher, M.
    Martinez-Bernal, G.
    Bria, E.
    Tortora, G.
    Soria, J.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1843 - S1843
  • [33] The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    Tang, Yanna
    Fang, Wenfeng
    Zhang, Yaxiong
    Hong, Shaodong
    Kang, Shiyang
    Yan, Yue
    Chen, Nan
    Zhan, Jianhua
    He, Xiaobo
    Qin, Tao
    Li, Ge
    Tang, Wenyi
    Peng, Peijian
    Zhang, Li
    ONCOTARGET, 2015, 6 (16) : 14209 - 14219
  • [34] PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
    Guibert, Nicolas
    Delaunay, Myriam
    Lusque, Annelle
    Boubekeur, Nadia
    Rouquette, Isabelle
    Clermont, Estelle
    Mourlanette, Jean
    Gouin, Sandrine
    Dormoy, Inge
    Favre, Gilles
    Mazieres, Julien
    Pradines, Anne
    LUNG CANCER, 2018, 120 : 108 - 112
  • [35] PD-L1, Tumor Mutational Burden (TMB) and Intracranial Outcomes in Patients with Non -Small Cell Lung Cancer (NSCLC) and Brain Metastases
    Adib, E.
    Nassar, A. H.
    Kwiatkowski, D. J.
    Aizer, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E213 - E213
  • [36] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
    Schakenraad, Alexandra
    Hashemi, Sayed
    Twisk, Jos
    Houda, Ilias
    Ulas, Ezgi
    Daniels, Johannes M. A.
    Veltman, Joris
    Bahce, I.
    LUNG CANCER, 2021, 162 : 36 - 41
  • [37] PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
    Meniawy, Tarek M.
    Lake, Richard A.
    McDonnell, Alison M.
    Millward, Michael J.
    Nowak, Anna K.
    LUNG CANCER, 2016, 93 : 9 - 16
  • [38] Evaluation of PD-L1/PD-1 on circulating tumor cells (CTCs) and on primary tumor in advanced non-small cell lung cancer (NSCLC)
    Kallergi, Galaktea
    Vetsika, Eleni Kyriaki
    Aggouraki, Despoina
    Lagoudaki, Eleni
    Koutsopoulos, Anastasios
    Koinis, Filippos
    Katsarlinos, Panagiotis
    Trypaki, Maria
    Stournaras, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    CANCER RESEARCH, 2017, 77
  • [39] Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer
    Takamori, Shinkichi
    Takada, Kazuki
    Azuma, Koichi
    Jogo, Yumiko
    Kinoshita, Fumihiko
    Kozuma, Yuka
    Matsubara, Taichi
    Haratake, Naoki
    Akamine, Takaki
    Toyokawa, Gouji
    Hirai, Fumihiko
    Tagawa, Tetsuzo
    Okamoto, Isamu
    Nakanishi, Yoichi
    Kawahara, Akihiko
    Akiba, Jun
    Oda, Yoshinao
    Maehara, Yoshihiko
    ANTICANCER RESEARCH, 2018, 38 (10) : 5903 - 5907
  • [40] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
    Aguilar, Elizabeth Jimenez
    Ricciuti, Biagio
    Gainor, Justin F.
    Nishino, Mizuki
    Adeni, Anika E.
    Subegdjo, Safiya
    Khosrowjerdi, Sara
    Peterson, Rachel
    Digumarthy, Subba
    Liu, Corinne
    Sauter, Jennifer L.
    Rizvi, Hira
    Arbour, Kathryn Cecilia
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345